UNICYCIVE THERAPEUTICS, INC. Investment Income, Interest
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Investment Income, Interest of $441.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. investment income, interest for the quarter ending 2026-06-30 was $441.00K, a 184.52% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. investment income, interest for the quarter ending 2026-03-31 was $394.00K, a 74.34% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. investment income, interest for the quarter ending 2025-12-31 was $351.00K, a 11.78% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. investment income, interest for the quarter ending 2025-09-30 was $279.00K, a 32.93% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. investment income, interest for fiscal 2025 was $1.01M, a 19.75% decline from fiscal 2024.
- UNICYCIVE THERAPEUTICS, INC. investment income, interest for fiscal 2024 was $1.26M, a 105.04% increase from fiscal 2023.
- UNICYCIVE THERAPEUTICS, INC. investment income, interest for fiscal 2023 was $615.00K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $441.00K 10-Q · filed 2026-08-12 | $836.00K 10-Q · filed 2026-08-12 | $1.19M derived: sum of 3 quarters · filed 2026-08-12 | $1.47M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $394.00K 10-Q · filed 2026-05-12 | $745.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.02M derived: sum of 3 quarters · filed 2026-05-12 | $1.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $351.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $630.00K derived: sum of 2 quarters · filed 2026-03-30 | $785.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.01M 10-K · filed 2026-03-30 |
| 2025-09-30 | $279.00K 10-Q · filed 2025-11-12 | $434.00K derived: sum of 2 quarters · filed 2026-08-12 | $661.00K 10-Q · filed 2025-11-12 | $974.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $155.00K 10-Q · filed 2026-08-12 | $381.00K 10-Q · filed 2026-08-12 | $695.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.11M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $226.00K 10-Q · filed 2026-05-12 | $540.00K derived: sum of 2 quarters · filed 2026-05-12 | $956.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.42M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $314.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $730.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.19M derived: sum of 3 quarters · filed 2026-03-30 | $1.26M 10-K · filed 2026-03-30 |
| 2024-09-30 | $416.00K 10-Q · filed 2025-11-12 | $878.00K derived: sum of 2 quarters · filed 2025-11-12 | $947.00K 10-Q · filed 2025-11-12 | $1.09M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $462.00K 10-Q · filed 2025-08-14 | $532.00K 10-Q · filed 2025-08-14 | $671.00K derived: sum of 3 quarters · filed 2025-08-14 | $898.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $69.00K 10-Q · filed 2025-05-14 | $209.00K derived: sum of 2 quarters · filed 2025-05-14 | $436.00K derived: sum of 3 quarters · filed 2025-05-14 | $670.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $367.00K derived: sum of 2 quarters · filed 2025-03-31 | $601.00K derived: sum of 3 quarters · filed 2025-03-31 | $615.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $227.00K 10-Q · filed 2024-11-13 | $461.00K derived: sum of 2 quarters · filed 2024-11-13 | $475.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $234.00K 10-Q · filed 2024-08-14 | $248.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $14.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |